No Data
No Data
Innovative phar (00399.HK) will hold a board of directors meeting on November 29 to approve the interim performance.
According to a statement on November 14 by the innovative phar (00399.HK), the board of directors will hold a meeting on Friday, November 29, 2024, to consider and approve the consolidated interim results for the six months ended September 30, 2024, for the company and its subsidiaries.
INNOVATIVE PHAR: NOTIFICATION OF BOARD MEETING
Innovative Phar intends to acquire a majority stake in Niraxx. Inc.
Innovative Phar (00399) announced that on November 12, 2024, the company, as an investor, has entered into a memorandum of understanding with the target (Niraxx. Inc.), indicating its intention to invest in the majority equity of the target. It is reported that the target is a limited company registered in Delaware, usa, mainly engaged in (a) developing the ai-driven virtual health platform SyncWell; (b) developing the brain neural technology service platform DeepSynaps; (c) integrating optical biological regulation technology into sportswear; and (d) developing
Innovative Phar (00399.HK) plans to invest in the field of AI in medical care and other areas.
Grants 12th of November: innovative phar (00399.HK) announced that on 12th November 2024, as an investor, the company has entered into a memorandum of understanding with the symbol, indicating the company's intention to invest in the potential investment of the majority of the target's equity. The target is a limited liability company registered in Delaware, USA, mainly engaged in (a) developing the ai-driven virtual health platform SyncWell, using ai applications to integrate and analyze dispersed health data, providing users with personalized real-time advice; and (b) developing innovative brain nerve technology service platform.
innovative phar (00399) is planning to acquire the majority equity of Niraxx. Inc.
Innovative Phar (00399) announced that on November 12, 2024, the company, as an investor, has already...
Express News | Innovative Pharmaceutical Biotech - to Invest in Niraxx. Inc.
No Data
No Data